Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Revolutions stories

Jul 7, 2026

European Medicines Agency Fast-Tracks Review of Revolution Medicines' Experimental Pancreatic Cancer Pill

The EMA has granted accelerated assessment to Revolutions' experimental pancreatic cancer drug, potentially shortening the review timeline for this treatment targeting a disease with limited therapeutic options.

Jul 7, 2026·1 source
00

Top claims

  • ▪The European Medicines Agency (EMA) began a rolling review of Revolution Medicines' experimental drug, daraxonrasib, on July 7, 2026
  • ▪While a rolling review can shorten the overall assessment timeline, medicines are held to the same standards as those in a conventional review
  • ▪Patients with metastatic pancreatic cancer whose disease progresses after initial treatment have limited therapeutic options and a poor prognosis

Subtopics

Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1Public healthcare1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Ebola outbreak

85 stories

Iran War

209 stories

Russia-Ukraine war

136 stories